Reductions in jak2 v617f allele burden with ruxolitinib treatment in comfort-ii, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (bat)

This article has no abstract
Epistemonikos ID: 78e70840965c84dcd12c517b6b4475611c728b70
First added on: Feb 05, 2025